Review: In CAD without HF, RAS inhibitors reduce deaths more than placebo but not active control.
Publication
, Journal Article
Lowenstern, A; Newby, LK
Published in: Ann Intern Med
April 18, 2017
Duke Scholars
Published In
Ann Intern Med
DOI
EISSN
1539-3704
Publication Date
April 18, 2017
Volume
166
Issue
8
Start / End Page
JC43
Location
United States
Related Subject Headings
- Stroke Volume
- Heart Failure
- General & Internal Medicine
- 3202 Clinical sciences
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Lowenstern, A., & Newby, L. K. (2017). Review: In CAD without HF, RAS inhibitors reduce deaths more than placebo but not active control. Ann Intern Med, 166(8), JC43. https://doi.org/10.7326/ACPJC-2017-166-8-043
Lowenstern, Angela, and L Kristin Newby. “Review: In CAD without HF, RAS inhibitors reduce deaths more than placebo but not active control.” Ann Intern Med 166, no. 8 (April 18, 2017): JC43. https://doi.org/10.7326/ACPJC-2017-166-8-043.
Lowenstern A, Newby LK. Review: In CAD without HF, RAS inhibitors reduce deaths more than placebo but not active control. Ann Intern Med. 2017 Apr 18;166(8):JC43.
Lowenstern, Angela, and L. Kristin Newby. “Review: In CAD without HF, RAS inhibitors reduce deaths more than placebo but not active control.” Ann Intern Med, vol. 166, no. 8, Apr. 2017, p. JC43. Pubmed, doi:10.7326/ACPJC-2017-166-8-043.
Lowenstern A, Newby LK. Review: In CAD without HF, RAS inhibitors reduce deaths more than placebo but not active control. Ann Intern Med. 2017 Apr 18;166(8):JC43.
Published In
Ann Intern Med
DOI
EISSN
1539-3704
Publication Date
April 18, 2017
Volume
166
Issue
8
Start / End Page
JC43
Location
United States
Related Subject Headings
- Stroke Volume
- Heart Failure
- General & Internal Medicine
- 3202 Clinical sciences
- 11 Medical and Health Sciences